Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (81-90 of 196) with videos related to

Pageof 20
Sort By:
Seminars in Thrombosis and Hemostasis|April 1, 1985
Studies on the profibrinolytic actions of heparin and its fractionsJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Burns : Journal of the International Society for Burn Injuries|January 12, 2000
Antithrombin III concentrate in the acute phase of thermal injuryA Kowal-Vern, V McGill, J M Walenga, et al.
Clinical Chemistry|February 1, 1983
Diagnostic efficacy of newer synthetic-substrates methods for assessing coagulation variables: a critical overviewJ Fareed, H L Messmore, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1984
Neonatal and maternal hemostasis: value of molecular markers in the assessment of hemostatic statusC R Suarez, C E Menendez, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1991
Neutralization of recombinant hirudin: some practical considerationsJ Fareed, J M Walenga, D Hoppensteadt, et al.
Thrombosis Research|December 1, 1991
In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole bloodB Kaiser, J Fareed, J M Walenga, et al.
The American Journal of Cardiology|September 16, 1998
Low-molecular-weight heparins: pharmacologic profile and product differentiationJ Fareed, W Jeske, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723K Malinowska, O Iqbal, D A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndromeS Ahmad, J M Walenga, W P Jeske, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
Biochemical and pharmacologic profile of defined molecular weight fractions of heparinD A Hoppensteadt, W Jeske, A Ahsan, et al.
Pageof 20

Showing results (81-90 of 196) with videos related to

Sort By:
Pageof 20
Seminars in Thrombosis and Hemostasis|April 1, 1985
Studies on the profibrinolytic actions of heparin and its fractionsJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Burns : Journal of the International Society for Burn Injuries|January 12, 2000
Antithrombin III concentrate in the acute phase of thermal injuryA Kowal-Vern, V McGill, J M Walenga, et al.
Clinical Chemistry|February 1, 1983
Diagnostic efficacy of newer synthetic-substrates methods for assessing coagulation variables: a critical overviewJ Fareed, H L Messmore, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1984
Neonatal and maternal hemostasis: value of molecular markers in the assessment of hemostatic statusC R Suarez, C E Menendez, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1991
Neutralization of recombinant hirudin: some practical considerationsJ Fareed, J M Walenga, D Hoppensteadt, et al.
Thrombosis Research|December 1, 1991
In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole bloodB Kaiser, J Fareed, J M Walenga, et al.
The American Journal of Cardiology|September 16, 1998
Low-molecular-weight heparins: pharmacologic profile and product differentiationJ Fareed, W Jeske, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723K Malinowska, O Iqbal, D A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndromeS Ahmad, J M Walenga, W P Jeske, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
Biochemical and pharmacologic profile of defined molecular weight fractions of heparinD A Hoppensteadt, W Jeske, A Ahsan, et al.
Pageof 20